Solventum Corporation (NYSE:SOLV) Receives $83.67 Consensus PT from Brokerages

Solventum Corporation (NYSE:SOLV) has been assigned a consensus recommendation of “Hold” from the thirteen analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $81.9091.

Several analysts have weighed in on the company. Piper Sandler dropped their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday. KeyCorp boosted their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Wells Fargo & Company lowered their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. Finally, Stifel Nicolaus cut their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th.

Hedge Funds Weigh In On Solventum

Several hedge funds have recently bought and sold shares of the company. Independent Franchise Partners LLP lifted its holdings in Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after buying an additional 2,456,451 shares during the period. State Street Corp lifted its holdings in shares of Solventum by 2.0% during the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after acquiring an additional 124,490 shares during the last quarter. Davis Selected Advisers lifted its position in Solventum by 12.7% in the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after buying an additional 702,461 shares during the last quarter. Boston Partners grew its position in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Solventum by 20.0% during the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after purchasing an additional 763,308 shares during the last quarter.

Solventum Stock Down 2.6%

NYSE SOLV opened at $79.22 on Tuesday. The stock has a fifty day moving average of $77.20 and a 200-day moving average of $74.22. The stock has a market capitalization of $13.72 billion, a P/E ratio of 9.71, a price-to-earnings-growth ratio of 1.25 and a beta of 0.66. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07.

Solventum (NYSE:SOLV) last released its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts forecast that Solventum will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.